Table 2 Overall responses

From: First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

 

Aumolertinib + Apatinib (N = 53)

Aumolertinib (N = 51)

Confirmed objective response

 No. of patients with confirmed objective response

42

30

 % of patients (95% CI)

79 (66–88)

59 (45–72)

Best overall response–no. (%)

 Complete response

2 (4)

0 (0)

 Partial response

40 (76)

30 (59)

 Stable disease

6 (11)

15 (29)

 Progression disease

0 (0)

3 (6)

 Not evaluated

5 (9)

3 (6)

CNS objective response

 No. of patients with CNS metastasis

12

14

 No. of patients with CNS objective response

10

6

 % of patients (95% CI)

83 (62–100)

43 (17–69)

Time to response–months

 Median (95% CI)

1.6 (1.5–2.9)

1.6 (1.5–2.9)

Duration of response–months

 Median (95% CI)

NR (NR–NR)

22.3 (11.9–NR)

  1. CI confidence interval, NR not reached
Back to article page